Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
LLY's manufacturing investments and pipeline strength, especially tirzepatide and retatrutide, position it to outpace Novo Nordisk A/S in the GLP-1/obesity market. NVO faces 2026 revenue and profit declines due to U.S. pricing pressures, patent expiries, and manufacturing disadvantages despite a strong dividend yield. LLY's market leadership, superior growth, and manufacturing scale suggest upside remains, while NVO's near-term outlook is pressured despite long-term duopoly potential. Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios. Learn More » Fabricio Rosa/iStock via Getty Images Investment Overview - Lilly's Growth Defies Doubters, Novo's Losses Defy Bulls Sometimes in the world of investing, valuations and metrics tell the wrong story - or is it simply a case of how you interpret those metrics? More on my IG service If you are interested in keeping up to date with stocks making
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk: Pfizer weight loss drug offers credible new competition [Yahoo! Finance]Yahoo! Finance
- Patient preference is leaning towards Eli Lilly's weight loss drugs, says Guggenheim's Fernandez [CNBC]CNBC
- Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge [Yahoo! Finance]Yahoo! Finance
- Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge [Yahoo! Finance Canada]Yahoo! Finance Canada
- Wegovy pill in high demand in weeks since launch, Novo Nordisk says [MSNBC.com]MSNBC.com
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/4/26 - Form IRANNOTICE
- 2/4/26 - Form 20-F
- 2/4/26 - Form 6-K
- NVO's page on the SEC website